Phoenix Biotech Acquisition Corp. (PBAXU) News
Filter PBAXU News Items
PBAXU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PBAXU News Highlights
- PBAXU's 30 day story count now stands at 2.
- Over the past 19 days, the trend for PBAXU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PBAXU are NOV, ETNB and LEA.
Latest PBAXU News From Around the Web
Below are the latest news stories about Phoenix Biotech Acquisition Corp that investors may wish to consider to help them evaluate PBAXU as an investment opportunity.
Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021Oakland, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the holders of the Company’s units may elect to separately trade the Class A common shares and warrants underlying the units commencing on November 26, 2021. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “PBAXU” and the |
89bio Announces Appointment of Kathy LaPorte to its Board of DirectorsSAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry lea |
Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment OptionOakland, CA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the completion of its initial public offering of 17,500,000 units at a price of $10.00 per unit, which includes 2,000,000 units issued pursuant to the exercise of the underwrit |